golcadomide (CC-99282) / BMS - LARVOL DELTA

Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma (clinicaltrials.gov) - P2 | N=83 | Recruiting | Sponsor: M.D. Anderson Cancer Center | Active, not recruiting ➔ Recruiting | N=33 ➔ 83

Enrollment change • Enrollment open • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Oncology

Mosunetuzumab (Mosun) or glofitamab (Glofit) in combination with golcadomide (Golca) demonstrates a manageable safety profile and encouraging efficacy in patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL) (ASH 2025) - P1 | "In Arm 2, ptsreceived intravenous obinutuzumab pretreatment on C1D1 and Glofit on C1D8 (2.5mg), D15 (10mg),then D1 of subsequent cycles (30mg); oral Golca was given daily from C2 or C3 onwards (D1–10; 21-daycycles) in dose escalation (0.2 or 0.4mg). Early data suggest Mosun/Glofit+Golca is an active regimen with a manageable safetyprofile consistent with the risks of individual agents. No new safety signals were observed; CRS eventswere low grade. Neutropenia was the most common overlapping toxicity and was manageable withprophylactic and therapeutic G-CSF."

Clinical • Combination therapy • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • CNS Disorders • Cognitive Disorders • Developmental Disorders • Diffuse Large B Cell Lymphoma • Febrile Neutropenia • Follicular Lymphoma • Hematological Disorders • Hematological Malignancies • Herpes Zoster • Infectious Disease • Large B Cell Lymphoma • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Thrombocytopenia • Varicella Zoster • CRBN • IKZF1

Golcadomide (GOLCA), a potential, first-in-class, oral CELMoD™ agent, ± rituximab (R) in patients with Relapsed/Refractory follicular lymphoma (R/R FL): Phase 1/2 study extended follow-up Results (ASH 2025) - P1/2, P3 | "Median number of prior treatments was 4.5 (range, 2–6) in Part A and 3 (range, 1–12)in Part B Cohort D. Approximately one-third of the treated patients were exposed to prior T-cell–redirecting therapy, approximately one-third had prior lenalidomide (len) exposure, and approximatelyone-third were refractory to the last regimen received. A higher ORR/CRR and similar tolerability were observed with GOLCA 0.4 mg + R vsGOLCA 0.2 mg + R, including in patients with prior len-based and/or T-cell–redirecting treatment. Thesedata support continued development of GOLCA 0.4 mg + R as a fixed-duration, chemotherapy-free,outpatient option in the ongoing Phase 3 GOLSEEK-4 study in 2L+ FL (NCT06911502)."

Clinical • P1/2 data • Cardiovascular • Febrile Neutropenia • Follicular Lymphoma • Gastroenterology • Gastrointestinal Disorder • Infectious Disease • Lymphoma • Neutropenia • Pulmonary Embolism • Respiratory Diseases • CRBN • IKZF1

Golcadomide, a Potential First-in-Class, Oral Celmod ± Rituximab in the Phase 1/2 CC-99282-NHL-001 Study: Long-Term Follow-Up Results of Patients With Relapsed/Refractory Follicular Lymphoma (SOHO 2026) - P3 | "In 0.2- and 0.4-mg groups, median prior therapy lines were 3 and 3; 32% and 32% had prior lenalidomide; 27% and 29% had prior T-cell-redirecting therapy; and 32% and 32% were refractory to last regimen. Golcadomide + rituximab continued to demonstrate promising efficacy with durable responses and no new safety signals. Efficacy was higher with 0.4 mg vs 0.2 mg, including patients with prior LEN and/or T-cell-redirecting therapies. These results support the phase 3 GOLSEEK-4 study of golcadomide ± rituximab as fixed-duration, chemotherapy-free outpatient treatment in 2L+ FL (NCT06911502)."

Clinical • P1/2 data • Follicular Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CRBN • IKZF1

GOLCADOMIDE, A CEREBLON E3 LIGASE MODULATOR (CELMoD) AGENT ± RITUXIMAB, IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: UPDATED PHASE 1/2 RESULTS (ICML 2025) - P1/2 | "As of 30 Dec 2024, 12 pts received GOLCA in Part A. 22 and 38 received 0.2 and 0.4 mg GOLCA+R in Part B; median (mdn; range) time from initial diagnosis was 59 months (mo) (10–420), mdn prior Tx lines was 3 (1–12; 28% had T-cell–directed Tx, 30% lenalidomide [len], and 30% were refractory to last Tx). With additional f/u, GOLCA continued to show promising efficacy with durable responses and no new safety signal in heavily pretreated pts with R/R FL, including pts with prior len and/or T-cell–directed Tx. GOLCA 0.4 mg +R will be evaluated in the Ph3 GOLSEEK-4 study as a fixed-duration, chemo-free, outpatient option in R/R FL."

Clinical • P1/2 data • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Oncology • CRBN • IKZF1

GOLCADOMIDE (GOLCA), A CEREBLON E3 LIGASE MODULATOR (CELMOD™) AGENT ± RITUXIMAB (R), IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (R/R FL): UPDATED PHASE 1/2 STUDY RESULTS (EHA 2025) - P1/2 | "Primary objectives included safety and RP2D determination.As of 30 Dec 2024, 12 pts received GOLCA in Part A, and 22 and 38 received 0.2mg and 0.4mg GOLCA+R in Part B. In Part B, median time (range) from initial diagnosis was 59 mo (10-420), median prior Tx lines was 3 (1-12), 28% had prior T-cell-directed Tx, 30% had prior lenalidomide (len) and 30% were refractory to last Tx.In Part A, 4 pts completed 2 y of GOLCA, remaining in remission at last f/u; 8 discontinued (d/c) due to PD. With additional f/u, GOLCA continued to show promising efficacy with durable responses and no new safety signals. A higher ORR and similar tolerability were observed with GOLCA 0.4mg +R vs GOLCA and GOLCA 0.2mg +R, including in pts with prior len-based and/or T-cell-directed Tx. These data support continued development of GOLCA 0.4mg +R as a fixed-duration, chemo-free, outpatient option in R/R FL, to be evaluated in the Ph3 GOLSEEK-4 study."

Clinical • P1/2 data • Anemia • Febrile Neutropenia • Follicular Lymphoma • Immune Modulation • Immunology • Infectious Disease • Lymphoma • Neutropenia • Targeted Protein Degradation • CRBN • IKZF1

Golcadomide (GOLCA; CC-99282), a Potential First-in-Class Oral CELMoD™ Agent, With R-CHOP, As First-line (1L) Therapy in Aggressive B-Cell Lymphoma (a-BCL): Safety and Efficacy in an Open-Label, Multicenter, Phase 1b Trial (SOHO 2024) - P1 | "The ongoing CC-220-DLBCL-001 trial of GOLCA+R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) (NCT04884035) has shown manageable safety and encouraging efficacy in untreated a-BCL. GOLCA+R-CHOP had a high rate of durable CMRs irrespective of cell of origin; promising 12-month progression-free survival, including in HR patients; and a manageable safety profile without compromising curative treatment. This supports the randomized phase 3 GOLSEEK-1 trial of untreated HR LBCL."

Clinical • P1 data • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

GOLSEEK-1: A PHASE 3, DOUBLE-BLIND, RANDOMIZED STUDY OF GOLCADOMIDE + R-CHOP VERSUS PLACEBO + R-CHOP IN PATIENTS WITH PREVIOUSLY UNTREATED, HIGH-RISK, LARGE B-CELL LYMPHOMA (ICML 2025) - P3 | "Introduction: Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is standard treatment (Tx) for diffuse large B-cell lymphoma (DLBCL) and is curative in ≈60–70% of patients (pts)...In the phase 1b study CC-220-DLBCL-001, GOLCA + R-CHOP was well tolerated, with promising activity and combinability and high rates of durable responses irrespective of COO in pts with previously untreated aggressive BCL, including HR pts...Key secondary endpoints include PFS in non–high-grade BCL, event-free survival, independently assessed complete metabolic response, undetectable minimal residual disease by PhasED-Seq, and overall survival. This study is recruiting globally at 309 sites in 36 countries."

Clinical • P3 data • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • BCL2 • CRBN • IKZF1

Golcadomide—A Potential First-in-Class Oral CELMoD Combined With Pola-R-CHP in Frontline Aggressive B-Cell Lymphoma: Safety and 12-Month Efficacy (SOHO 2026) - "These data support the potential of golcadomide+R-CHOP/Pola-R-CHP to improve outcomes in 1L high-risk ABCL ABCL: aggressive B-cell lymphoma; ctDNA: circulating tumor DNA; DLBCL: diffuse large B-cell lymphoma; ECOG: Eastern Cooperative Oncology Group; IPI: International Prognostic Index; LDH: lactate dehydrogenase; PhasED-Seq: phased variant enrichment and detection sequencing; Pola-R-CHP: polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, prednisone; R-CHOP: rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone. Golcadomide+Pola-R-CHP demonstrated a predictable and manageable safety profile. The addition of golcadomide did not compromise median RDI of Pola-R-CHP. Golcadomide (0.4 mg)+Pola-R-CHP demonstrated high durable CMRs, MRD negativity, and promising 12-month PFS."

Clinical • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CRBN • IKZF1

GOLCADOMIDE (GOLCA [CC-99282]), A POTENTIAL FIRST-IN-CLASS ORAL CELMOD™ AGENT, PLUS R-CHOP IN PATIENTS (PTS) WITH UNTREATED AGGRESSIVE B-CELL LYMPHOMA (A-BCL): SAFETY AND 12-MONTH EFFICACY RESULTS (EHA 2024) - P1 | "CC-220-DLBCL-001 (NCT04884035) is an ongoing phase 1b,open-label, multicenter, dose escalation/expansion trial to assess safety and preliminary 1L GOLCA+R-CHOPefficacy in a-BCL. GOLCA at DL1 with R-CHOP resulted in a high rate of durable CMRs irrespective of COO and a promising 12-month PFS in the overall and HR populations. GOLCA+R-CHOP demonstrated a manageable safety profile; theaddition of GOLCA to R-CHOP did not compromise curative treatment. These data support the initiation of therandomized phase 3 trial GOLSEEK-1 of GOLCA+R-CHOP versus R-CHOP as 1L treatment in pts with HR DLBCL."

Clinical • Diffuse Large B Cell Lymphoma • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology • Thrombocytopenia • IKZF1

SAFETY AND EFFICACY OF GOLCADOMIDE, A POTENTIAL FIRST-IN-CLASS CELMOD AGENT ± RITUXIMAB IN A PHASE 1/2 OPEN-LABEL STUDY OF PATIENTS WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL) (EHA 2024) - P1/2 | "GOLCA±RTX showed encouraging efficacy in heavily pretreated pts with R/R FL, including in pts with LEN-refractory disease and post CAR T cell relapses. Longer follow-up with GOLCA monotherapy shows responsesare durable. GOLCA can be safely combined with RTX, with a similar safety profile to that previously reportedfor GOLCA monotherapy."

Clinical • P1/2 data • Cardiovascular • Diffuse Large B Cell Lymphoma • Febrile Neutropenia • Follicular Lymphoma • Hematological Disorders • Hematological Malignancies • Lymphoma • Neutropenia • Oncology • Pulmonary Embolism • Respiratory Diseases • Targeted Protein Degradation • CRBN • IKZF1

Golcadomide (GOLCA) Plus R-CHOP Has High Minimal Residual Disease (MRD) Negativity across High-Risk, Untreated Aggressive B-Cell Lymphoma (a-BCL) (ASH 2024) - P1 | "CC-220-DLBCL-001 (NCT04884035) is an ongoing phase 1b, open-label, multicenter, dose-escalation/expansion trial to assess safety and preliminary 1L GOLCA + R-CHOP efficacy in a-BCL. Although pt numbers were small, the data suggest that 0.4 mg is efficacious in high-risk ctDNA and high-genomic risk pts, independent of COO, and support the 0.4 mg GOLCA + R-CHOP regimen in the randomized phase 3 trial GOLSEEK-1. Interim MRD- may play a role in future adaptive trial designs."

Minimal residual disease • Residual disease • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Targeted Protein Degradation • CRBN • IKZF1 • TP53

GOLCADOMIDE (GOLCA), A CEREBLON E3 LIGASE MODULATOR (CELMOD™) AGENT, ± RITUXIMAB (R) IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): UPDATED PHASE 1/2 STUDY RESULTS (EHA 2025) - P1/2 | "With additional f/u, GOLCA+R continued to demonstrate a manageable safety profile with no new safety signals. Durable responses were shown in heavily pre-treated patients with R/R DLBCL. Responses were independent of cell of origin and tumor microenvironment status."

Clinical • IO biomarker • P1/2 data • Anemia • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Immune Modulation • Immunology • Infectious Disease • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology • Pneumonia • Respiratory Diseases • Targeted Protein Degradation • BCL2 • CRBN • IKZF1 • TP53

Golcadomide (GOLCA), a potential, first-in-class, oral CELMoD™ agent, plus R-CHOP in patients (Pts) with previously untreated aggressive B-cell lymphoma (a-BCL): 24-month efficacy Results (ASH 2025) - P1, P3 | "GOLCA drivesthe closed, active conformation of cereblon to induce rapid and deep degradation of Ikaros and Aiolos,leading to direct cell killing (agnostic of cell of origin [COO]) and immunomodulatory activity.CC-220-DLBCL-001 (NCT04884035) is an ongoing Phase 1b, open-label, multicenter trial to assess safetyand preliminary efficacy of GOLCA+R-CHOP in previously untreated a-BCL. GOLCA+R-CHOP demonstrated a predictable and manageablesafety profile with low rates of non-hematologic AEs; addition of GOLCA to R-CHOP did not compromiseSOC delivery. These data continue to show that GOLCA 0.4mg, when added to SOC Tx, has a potential tocure more previously untreated pts with HR LBCL and support the ongoing Phase 3 trial, GOLSEEK-1, inthis population (NCT06356129)."

Clinical • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Febrile Neutropenia • Gastrointestinal Disorder • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Thrombocytopenia • CRBN • IKZF1

Golcadomide (GOLCA), a potential, first-in-class, oral CELMoD™ agent, ± rituximab (R) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Phase 1/2 study extended follow-up Results (ASH 2025) - P1/2 | "GOLCA+ R induced a decrease in circulating tumor DNA across tumor variants. These data support the ongoingdevelopment of GOLCA + R in patients with R/R non-Hodgkin lymphoma."

Clinical • P1/2 data • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Infectious Disease • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Pneumonia • Respiratory Diseases • CRBN • IKZF1

Golseek-4: A Phase 3, randomized study of golcadomide, a potential, first-in-class, oral CELMoD™ agent, plus rituximab versus Investigator's choice in patients with Relapsed/Refractory follicular lymphoma who have received ≥1 line of systemic therapy (ASH 2025) - P3 | "Patients randomized to IC will receive rituximab-lenalidomide (lenalidomide 20mg Days 1–21 every 28 days plus rituximab) for 5 cycles followed by lenalidomide monotherapy for 7cycles (total of 12 cycles) or rituximab-chemotherapy (R-CHOP or R-Bendamustine) for 6 cycles.Randomization will be stratified by progression of disease within 24 months vs >24 months from initialtherapy, number of prior systemic regimens (2L vs 3L+), and comparator IC regimen. Patients will be followed for up to five years from the last patient's first visit.GOLSEEK-4 will evaluate the safety and efficacy of golcadomide + rituximab as a fixed-duration,chemotherapy-free, outpatient treatment for patients with R/R FL, who have received ≥1 line of systemictherapy as compared to Investigator's choice of R-chemo or R-len. Recruitment started July 2025.AcknowledgementBMS Artificial Intelligence was used to revise existing text with human author oversight."

Clinical • P3 data • B Cell Lymphoma • CNS Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Indolent Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • CRBN • IKZF1

Golcadomide, a CELMoD Agent, With or Without Rituximab in Patients With Relapsed/Refractory Follicular Lymphoma (R/R FL): Updated Phase 1/2 Results (SOHO 2025) - P1/2, P3 | " As of December 30, 2024, 12 patients received golcadomide in A, and 22 and 38 received 0.2 mg and 0.4 mg golcadomide+rituximab in B. Median time from initial diagnosis, 59 months; median prior lines of therapy, 3 (28% T-cell– directed; 30% lenalidomide; 30% refractory to last therapy). Golcadomide demonstrated promising efficacy, with durable responses and no new safety signals in heavily pretreated patients with R/R FL. These results support investigation of golcadomide (0.4 mg) with rituximab in the phase 3 GOLSEEK-4 study in 2L+ FL (NCT06911502). Presented at 2025 EHA Annual Congress; modified using BMS AI."

Clinical • P1/2 data • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Oncology • CRBN • IKZF1

GOLSEEK-4: A Multicenter Phase 3 Randomized Open-Label Study Comparing Efficacy and Safety of Golcadomide + Rituximab Vs Investigator's Choice in Patients With Relapsed/Refractory Follicular Lymphoma (SOHO 2025) - P3 | "Commonly used treatments for relapsed/refractory (R/R) FL include chemoimmunotherapy or rituximab-lenalidomide. GOLSEEK-4 will evaluate the safety and efficacy of golcadomide+rituximab as a fixed-duration chemotherapy-free outpatient treatment for patients with R/R FL who have received at least one line of systemic therapy. Presented at 2025 EHA Annual Congress; modified using BMS AI."

Clinical • P3 data • Follicular Lymphoma • Hematological Malignancies • Indolent Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CRBN • IKZF1

Golcadomide (GOLCA) ± Rituximab (RTX) Demonstrates Durable Efficacy and Is Well Tolerated in Patients (pts) with Relapsed/Refractory Follicular Lymphoma (R/R FL): Updated Results from the Phase 1/2 CC-99282-NHL-001 Study (ASH 2024) - P1/2, P2 | "In the GOLCA mono and + RTX cohorts, 9/19 (47%) and 13/43 (30%) pts had received prior lenalidomide (len)-based therapy, with 5/9 and 7/13 having len-refractory disease, respectively. Treatment with fixed-duration GOLCA mono led to durable responses including a subset of pts remaining treatment free, without progression at extended follow up. These data further support development of GOLCA + RTX as a fixed-duration, chemotherapy-free, outpatient treatment option in pts with R/R FL, and also pts with newly diagnosed advanced stage FL (NCT06425302)."

Clinical • P1/2 data • Anemia • Cardiovascular • Diffuse Large B Cell Lymphoma • Fatigue • Febrile Neutropenia • Follicular Lymphoma • Infectious Disease • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Pneumonia • Pulmonary Embolism • Respiratory Diseases • IKZF1

Model-informed optimal dose selection of golcadomide in combination with R-CHOP in patients with previously untreated aggressive B-cell lymphoma. (PubMed, Br J Clin Pharmacol) - P1 | "The integrated MIDD evaluation conducted in this study provided a quantitative and mechanism-based rationale for the optimal dose selection of golcadomide in previously untreated aggressive B-cell lymphoma. The findings also highlight the value of a systematic MIDD framework for dose optimization in alignment with FDA's Project Optimus initiative and provide an example for oncology drug dose selection in combination therapy settings."

Journal • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology • Thrombocytopenia • IKZF1

TREATMENT OF NEWLY-DIAGNOSED FOLLICULAR LYMPHOMA WITH RITUXIMAB, GOLCADOMIDE +/- NIVOLUMAB- INTERIM ANALYSIS OF THE PHASE II TOP-FLOR STUDY (ICML 2025) - P2 | "Background: Standard rituximab (R) +lenalidomide (R2) or chemoimmunotherapy is effective in treatment-naïve follicular lymphoma (TN FL) but is associated with Grade 3–4 AE rates > 65% with elderly patients (pts) overrepresented...We have demonstrated immune augmentation, safety and efficacy of PD1/PDL1i nivolumab (N) +rituximab, and atezolizumab-obinutuzumab-radiotherapy in TN FL (Chong ASCO 2024; Barraclough Blood Adv 2025)... This is the first study to demonstrate that Rituximab-golcadomide +/-nivolumab is a highly effective combination therapy in TN FL with manageable toxicity, most commonly neutropenia and infection. Differences between arms could not be elucidated in this preplanned interim analysis. The study continues recruitment."

P2 data • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Oncology • CRBN • PD-1

Golcadomide With Pemetrexed, Rituximab, and Dexamethasone for Relapsed and Refractory CNS Lymphomas (clinicaltrials.gov) - P1 | N=18 | Not yet recruiting | Sponsor: Allison Winter | Initiation date: Jun 2026 ➔ Oct 2026

Trial initiation date • B Cell Lymphoma • CNS Lymphoma • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Secondary Central Nervous System Lymphoma

Golcadomide, a Cereblon E3 Ligase Modulator (CELMoD) Agent, With or Without Rituximab in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Updated Phase 1/ 2 Results (SOHO 2025) - P1/2 | "Golcadomide+rituximab continues to demonstrate manageable safety with no new signals. Durable responses were observed in heavily pretreated patients, independent of cell-of-origin and tumor microenvironment status. These data support the ongoing development of golcadomide in patients with R/R non-Hodgkin lymphoma."

Clinical • IO biomarker • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CRBN • IKZF1

A Study to Evaluate the Pharmacokinetics and Safety of Golcadomide in Participants With Severe Renal Impairment and End-Stage Renal Disease Compared With Participants With Normal Renal Function (clinicaltrials.gov) - P1 | N=30 | Not yet recruiting | Sponsor: Bristol-Myers Squibb

New P1 trial • Chronic Kidney Disease • Nephrology • Renal Disease

Rituximab, golcadomide +/- nivolumab in treatment-naive follicular lymphoma: primary results of the investigator-led randomised Phase II TOP-FLOR study

Video